Rodiyax^®- N – Hyaluronic Acid

Hyaluronic acid occurs naturally in the synovial fluid of human joints, acting as a lubricant and shock absorber for cartilage and ligaments. Synovial fluid in joints affected by osteoarthritis has a much lower viscosity and elasticity than in healthy joints. Injecting hyaluronic acid into the joint can restore these properties and alleviate pain while improving joint mobility.

Rodiyax^®-N contains 30 mg of high molecular weight, ultra-pure, and natural hyaluronic acid dissolved in a physiological sodium chloride solution that is supplied in a 2 mL single-use prefilled syringe.

Rodiyax^®-N is indicated for the symptomatic treatment of mild to moderate osteoarthritis of the joints in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics.

Rodiyax^®-N should be injected by a healthcare professional using a healthcare facility-approved aseptic technique. Rodiyax^®-N is injected into the joint in a series of intra-articular injections 1 week apart for a total of 3 or 4 injections. After removal of the protective rubber cap on the tip of the syringe, securely attach a proper gauge needle (18-21 gauge) to the tip by a healthcare professional using a healthcare facility-approved aseptic technique. The healthcare provider should ensure proper penetration into joint synovial space before injecting Rodiyax^®-N.

A 2 mL syringe containing 30 mg high molecular weight hyaluronic acid in 18 mg sodium chloride solution and a leaflet.

Injecting hyaluronic acid into the joint can restore the viscosity and elasticity of the synovial fluid in joints and alleviate pain while improving joint mobility.

• Rodiyax^®-N should be stored in its original package at a temperature of 2-25°C and protected from freezing.
• Refrigerated Rodiyax^®-N should be allowed to reach room temperature (approximately 20 to 45 minutes) prior to use.

• The prefilled syringe is intended for single use only.
• The contents of the syringe should be used immediately after opening.
• Do not re-sterilize the syringe.
• It is recommended that patients avoid strenuous activity or prolonged (i.e., more than one hour) weight-bearing activities such as running or tennis within 48 hours following the intra-articular injection.
• If the blister package or syringe is opened or damaged, do not use it.
• The syringe and any unused material must be discarded immediately after the treatment session.
• Transient pain or swelling may occur after the intra-articular injection.
• Remove joint effusion, if present, before injecting Rodiyax^®-N.
• Safety and efficacy of Rodiyax^®-N have not been evaluated in pregnant or lactating women or children.

Rodiyax^®-N is manufactured by bacterial fermentation and is of non-animal origin, which significantly reduces the risk of allergic reactions or transmission of animal-borne diseases.
Rodiyax^®-N is highly similar to the natural hyaluronic acid found in human synovial fluid. Due to its high molecular weight, it remains in the joint for an extended period